tbuckley/cabot-search huggingface dataset:
Cyclamate Sweeteners
Authors: Thomas H. Jukes
Journal: JAMA (1976)

ON OCT 18, 1969, the Secretary of Health, Education, and Welfare, Mr Robert Finch, announced that "the artificial sweetener cyclamate was removed from the list of substances generally recognized as safe (GRAS) for use in food." In so doing, he invoked the "so-called Delaney amendment which states that any food additive must be removed from the market if it has been shown to cause cancer when fed to humans or animals." This announcement caused surprise and consternation both in the United States and other countries, for cyclamates had been in steadily increasing use since the early 1950s, and in 1959 had been put on the safe list for addition to foods. The ban is still making news. The discovery by Sveda in 1937 of a sweet substance lacking the aftertaste of saccharin started a train of research and development that led to the introduction of Sucaryl sodium, C<sub>6</sub>H
Helps and Hints in Nursing.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in the Figure
Authors: Douglas Johnson, Fei Ye, Anna Dewan
Journal: JAMA Oncology (2019)

titled "Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer," published online February 2, 2017, and also in the September 2017 issue of JAMA Oncology, 1 an error occurred in the statistical programming of the analysis.All analyses were recalculated, which resulted in changes to the population-attributable risk proportion estimates for some of the risk factors and combinations of risk factors, 2 most of which did not alter the conclusions.This article was corrected online.
The long term cost of antisocial behaviour in childhood is high and avoidable
Journal: BMJ (2001)

Evidence on health effects of housing improvements is scarce Despite strong observational evidence linking housing and health, it is still not known if housing improvements can improve health.Thomson et al (p 187) conducted a systematic review of studies of housing interventions on health.Although many of the studies found that health improved after the interventions, the studies were small and often did not adjust for potential confounding factors.
Benign Polyarthritis
Authors: J. S. Lawrence, P. H. Bennett
Journal: Annals of the Rheumatic Diseases (1960)

<h3>PURPOSE</h3> To document the response of mycotic aneurysms to antibiotic therapy and correlate these findings with patient outcome. <h3>METHODS</h3> Clinical findings, CT studies, and serial cerebral angiograms of patients with endocarditis related aneurysms seen over 10 years were retrospectively reviewed. <h3>RESULTS</h3> In 14 patients infective endocarditis was diagnosed. The patients presented with subarachnoid haemorrhage (4 patients), stroke (9 patients), and seizure (1 patient). CT findings were intracerebral hematoma (5 patients), infarcts (4 patients), subarachnoid hemorrhage (4 patients), and aneurysms (2 patients). On angiography, 10 (71%) patients had single aneurysms, and 4 (29%) patients had multiple aneurysms. Eighteen aneurysms were detected, of which 6 (33%) were centrally located, and 12 (66%) were located peripherally. The most common site was the peripheral middle cerebral artery (56%). Serial angiography during antibiotic treatment demonstrated complete resolution of 6 aneurysms (33%), with 12 aneurysms remaining after 6 weeks of treatment. Of the latter, there was no change in size in 6 aneurysms (33%), a decrease in size in 3 aneurysms (17%) and an increase in size in 3 aneurysms (17%). No new aneurysms appeared. Surgery was performed on 10 patients with residual aneurysms, 11 aneurysms being excised or clipped. After 6 weeks9 treatment, there was complete recovery in 7 (50%) patients, permanent neurologic deficits in 6 patients, and death from aneurysm rebleed in 1 patient. <h3>CONCLUSION</h3> Follow-up angiography is recommended in all patients with mycotic aneurysms to assess response to antibiotic therapy, to detect new aneurysms, and to identify those aneurysms with no response or with enlargement.
Autoantibodies in primary biliary cirrhosis: Analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes
Authors: S Fussey
Journal: Hepatology (1991)

Six components of the mammalian 2-oxo acid dehydrogenase complexes have previously been identified as M2 autoantigens in primary biliary cirrhosis. In this report, we present data showing that both polypeptidespecific and cross-reacting antibodies are present in patients' sera. Antibodies reacting with E2 of the pyruvate dehydrogenase complex cross-react with protein X but not with any other mammalian antigen. The main immunogenic region on protein X has been localized to within its single lipoyl domain. Polypeptide-specific antibodies bind to Elα and E1β of the pyruvate dehydrogenase complex. Antibodies reacting with the E2 polypeptides of the 2-oxoglutarate dehydrogenase complex and branched-chain 2-oxo acid dehydrogenase complex show some crossreactivity but do not recognize any of the antigens of the pyruvate dehydrogenase complex. Antibodies against the E2 component of the mammalian pyruvate dehydrogenase complex cross-react effectively with the corresponding protein from yeast but not with E2 from Escherichia coli. Antibody titer against mammalian antigens is significantly higher than against the bacterial antigens, arguing against a bacterial origin for primary biliary cirrhosis. (HEPATOLOGY 1991;13:467–474.)
Extracorporeal membrane oxygenation can be cost effective
Journal: BMJ (1998)

No clustering of anophthalmia occurs in England, but prevalence is higher in rural areas On p 905 Dolk et al describe a study set up to answer public concern after media allegations that clusters of babies were born with anophthalmia and microphthalmia in England and a link with pesticide exposure postulated.The results suggest little localised geographical clustering in babies born in 1988-94.However, the condition is more prevalent in rural areas and this observation requires confirmation and investigation.
Pediatric Hypertension
Authors: Samuel Kaplan
Journal: JAMA (1982)

It is refreshing to find a useful book written for clinicians by a single author. In the last decade, physicians who care for children have recognized the importance of measuring blood pressure as a part of the routine of physical examination. The foreword emphasizes that children with significant elevation of blood pressure can be treated successfully. It is not clear how to manage the common form of childhood hypertension, which is generally mild and of undefined etiology (so-called essential hypertension). The clinical applicability of the book is identified in the early chapters on evaluation and therapy of the hypertensive child and adolescent. These chapters are followed by discussions of the role of the renin-angiotensin system and other hormonal systems in blood pressure control and a concise review of hemodynamics and blood pressure. A major part of the text is devoted to clinical situations associated with hypertension, such as renal vascular
The right of privacy protects the doctor-patient relationship
Journal: JAMA (1990)

<h3>In Reply.—</h3> We applaud the well-designed study by Wiström et al that demonstrates that low-dose ID inoculation of adults with three 2-μg doses of a recombinant hepatitis B vaccine (Recombivax-HB, Merck Sharp &amp; Dohme) results in lower seroconversion rates and reduced levels of antibody to HBsAg compared with three 10-μg IM injections of the same product. These results are not unexpected. There is a positive correlation between dose and immune response regardless of the type of product used.<sup>1</sup>In our ID study we were able to use the more immunogenic plasma-derived Hepta
Insect Repellents
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Trend and Transplantation
Authors: E. J. H.
Journal: Annals of Internal Medicine (1963)

Editorials1 June 1963A Trend and TransplantationE. J. H.E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-58-6-1057 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThose clinical disciples of Northcote Parkinson who make a hobby of watching, appalled but fascinated, the geometrical proliferation of medical publications were busy for a while noting the births of journals devoted entirely to investigations of single organs or systems—Blood, Gut, andBrain. A like asexual trend—a budding-off from journals of laboratory science—has given usTransplantation, of which Volume 1, Number 1 appeared in January of this year, in part, perhaps, as noted by P. B. Medawar in an editorial in this first issue, to give "relief (to) the editors of more orthodox journals of immunology and pathology, who for... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1963Volume 58, Issue 6Page: 1057-1057KeywordsBirthBrainImmunologyResearch laboratoriesTransplantation ePublished: 1 December 2008 Issue Published: 1 June 1963 PDF downloadLoading ...
Editor’s Commentary
Authors: James T. Willerson
Journal: Circulation (2003)

ith this Supplement, Circulation is inaugurating a new educational effort for its readership.It is our intention to publish from time-to-time educationally oriented supplements that bring to our readership a full discussion of important topics in cardiovascular medicine.In this supplement, the Society for Vascular Medicine and Biology presents the initial Series of Monographs on Venous Thromboembolic Disease.Each of these papers has been reviewed by the Society, by Circulation's reviewers, and by the Editor.We shall focus on supplements that are truly educational, and that are meant to broaden the abilities of physicians, nurses, and technical support staff who see and care for patients with cardiovascular disease.Through this supplement, and ones that will follow in the coming months, the Editor and Associate Editors of Circulation believe that the readership will become better informed about selected aspects of cardiovascular disease and will be even better prepared to treat patients with these problems.
ATP11B mediates platinum resistance in ovarian cancer
Authors: Myrthala Moreno-Smith, J.B. Halder, Paul S. Meltzer, Tamas A. Gonda, Lingegowda S. Mangala, Rajesha Rupaimoole, Chunhua Lu, Archana S. Nagaraja, Kshipra M. Gharpure, Yu Kang, Cristian Rodriguez-Aguayo, Pablo E. Vivas-Mejia, Behrouz Zand, Rosemarie Schmandt, Hua Wang, Robert R. Langley, Nicholas B. Jennings, Cristina Ivan, Jeremy E. Coffin, Guillermo N. Armaiz, Justin Bottsford-Miller, Sang Bae Kim, Margaret S. Halleck, Mary J.C. Hendrix, William Bornman, Menashe Bar-Eli, Ju-Seog Lee, Zahid H. Siddik, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Journal of Clinical Investigation (2013)

Platinum compounds display clinical activity against a wide variety of solid tumors; however, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum export are examples of resistance mechanisms that limit the extent of DNA damage. Here, we report the discovery and characterization of the role of ATP11B, a P-type ATPase membrane protein, in cisplatin resistance. We found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin resistance in human ovarian cancer cell lines. ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. Combined therapy of cisplatin and ATP11B-targeted siRNA significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells. In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhances the export of cisplatin from cells. The colocalization of ATP11B with fluorescent cisplatin and with vesicular trafficking proteins, such as syntaxin-6 (STX6) and vesicular-associated membrane protein 4 (VAMP4), strongly suggests that ATP11B contributes to secretory vesicular transport of cisplatin from Golgi to plasma membrane. In conclusion, inhibition of ATP11B expression could serve as a therapeutic strategy to overcome cisplatin resistance.
Effects of Major Depression on Moment-in-Time Work Performance
Authors: P. S. Wang
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: Although major depression is thought to have substantial negative effects on work performance, the possibility of recall bias limits self-report studies of these effects. The authors used the experience sampling method to address this problem by collecting comparative data on moment-in-time work performance among service workers who were depressed and those who were not depressed. METHOD: The group studied included 105 airline reservation agents and 181 telephone customer service representatives selected from a larger baseline sample; depressed workers were deliberately oversampled. Respondents were given pagers and experience sampling method diaries for each day of the study. A computerized autodialer paged respondents at random time points. When paged, respondents reported on their work performance in the diary. Moment-in-time work performance was assessed at five random times each day over a 7-day data collection period (35 data points for each respondent). RESULTS: Seven conditions (allergies, arthritis, back pain, headaches, high blood pressure, asthma, and major depression) occurred often enough in this group of respondents to be studied. Major depression was the only condition significantly related to decrements in both of the dimensions of work performance assessed in the diaries: task focus and productivity. These effects were equivalent to approximately 2.3 days absent because of sickness per depressed worker per month of being depressed. CONCLUSIONS: Previous studies based on days missed from work significantly underestimate the adverse economic effects associated with depression. Productivity losses related to depression appear to exceed the costs of effective treatment.
The Limb-Deficient Child.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OFFICERS OF THE AMERICAN MEDICAL ASSOCIATION—1941-1942
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Table 2
Authors: Ashley Leberfinger, Donald Mackay, Dino Ravnic, Wendy King, Steven Belle, Anita Courcoulas
Journal: JAMA Surgery (2018)

Caroline E. Jones, MD, MSPH; Laura A. Graham, MPH; Melanie S. Morris, MD; Joshua S. Richman, MD, PhD; Robert H. Hollis, MD; Tyler S. Wahl, MD; Laurel A. Copeland, PhD; Edith A. Burns, MD; Kamal M. F. Itani, MD; Mary T. Hawn, MD, MPH
Clinicopathological conference: A case of unsuspected chronic inflammatory disease.
Journal: BMJ (1973)

In hypercapnic chronic respiratory failure red cell volume correlates with the arterial oxygen tension during the quiescent phase of the disease.During an acute exacerbation measurement of the red cell volume can give a reasonable index of the arterial oxygen tension existing in the previous quiescent state.This level of arterial oxygen tension appears to determine the toler- ance of the individual to treatment with oxygen.
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
Authors: Atsushi Ohtsu, Takayuki Yoshino, Mona M. Wahba, Fabio M. Benedetti, Robert J. Mayer, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2015)

3564 Background: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil hydrochloride, at a molar ratio of 1:0.5 (weight ratio, 1:0.471). The efficacy and safety of TAS-102 in patients (pts) with metastatic colorectal cancer refractory/intolerant to standard therapies were evaluated in the RECOURSE trial; enrollment criteria included ≥ 2 prior lines of standard chemotherapy. Primary results of RECOURSE demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 vs placebo (PBO) (hazard ratio [HR] = 0.68 and 0.48 for OS and PFS, respectively; both P< 0.0001). Methods: RECOURSE data were evaluated for efficacy and safety, including rate of hospitalizations, of TAS-102 vs PBO by each geographic subgroup of US, EU, and Japan (JP). Results: Of 768 pts, 99 US (mean age, 60 y), 403 EU (mean age, 62 y), and 266 JP (mean age, 62 y) pts were randomized to receive TAS-102 or PBO. Median OS with TAS-102 vs PBO was 6.5 mo vs 4.3 mo in US pts, 6.8 mo vs 4.9 mo in EU pts, and 7.8 mo vs 6.7 mo in JP pts. HRs for OS and PFS for US, EU, and JP pts all favored TAS-102 (Table). There were no marked differences among the US, EU, and JP subgroups with respect to overall incidence of adverse events (AEs), ≥ Grade 3 AEs, serious AEs (SAEs), or hospitalizations. Conclusions: Similar to the overall RECOURSE population, OS and PFS benefits were observed in each geographic subgroup randomized to TAS-102 vs PBO, with an acceptable safety profile. Clinical trial information: NCT01607957. Intent to Treat US EU JP TAS-102 (n = 64) thPBO th(n = 35) thTAS-102 th(n = 271) thPBO th(n = 132) thTAS-102 th(n = 178) thPBO (n = 88) OS HR [95% CI] 0.56 [0.34, 0.94] P= 0.0277 0.62 [0.48, 0.80] P= 0.0002 0.75 [0.57, 1.00] P= 0.047 PFS HR [95% CI] 0.43 [0.26, 0.69] P= 0.0004 0.41 [0.33, 0.52] P< 0.0001 0.58 [0.44, 0.75] P< 0.0001 As Treated TAS-102(n = 64) PBO(n = 35) TAS-102(n = 270) PBO(n = 131) TAS-102(n = 178) PBO(n = 88) Any AE, % 96.9 100 98.5 91.6 99.4 92.0 AEs ≥ Grade 3, % 73.4 45.7 70.7 55.0 66.3 50.0 Serious AEs, % 28.1 31.4 30.4 32.1 26.4 38.6 Hospitalizations, all reasons, % 26.6 34.3 31.1 34.4 29.2 40.9